Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Average Recommendation of “Moderate Buy” from Brokerages

Cardiff Oncology, Inc. (NASDAQ:CRDF) has earned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $11.1250.

Several brokerages have recently issued reports on CRDF. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Cardiff Oncology in a research note on Wednesday, January 28th. Noble Financial initiated coverage on Cardiff Oncology in a research report on Monday, January 5th. They set an “outperform” rating and a $12.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Cardiff Oncology by 50.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,319 shares of the company’s stock valued at $108,000 after purchasing an additional 11,497 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Cardiff Oncology by 18.8% in the first quarter. Rhumbline Advisers now owns 63,142 shares of the company’s stock worth $198,000 after acquiring an additional 9,970 shares in the last quarter. SteelPeak Wealth LLC lifted its stake in shares of Cardiff Oncology by 23.2% in the second quarter. SteelPeak Wealth LLC now owns 22,800 shares of the company’s stock worth $72,000 after acquiring an additional 4,300 shares in the last quarter. Blair William & Co. IL boosted its holdings in Cardiff Oncology by 44.1% in the second quarter. Blair William & Co. IL now owns 2,524,118 shares of the company’s stock valued at $7,951,000 after purchasing an additional 772,844 shares during the last quarter. Finally, Integrity Alliance LLC. acquired a new stake in Cardiff Oncology during the 2nd quarter valued at approximately $41,000. 16.29% of the stock is owned by institutional investors and hedge funds.

Cardiff Oncology Price Performance

NASDAQ CRDF opened at $1.58 on Thursday. The company has a market cap of $106.43 million, a P/E ratio of -2.00 and a beta of 1.33. Cardiff Oncology has a 12 month low of $1.55 and a 12 month high of $4.99. The company has a 50-day moving average of $2.56 and a 200-day moving average of $2.41.

Cardiff Oncology (NASDAQ:CRDF) last released its earnings results on Thursday, November 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03. The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.12 million. Cardiff Oncology had a negative net margin of 10,064.27% and a negative return on equity of 77.21%. As a group, equities research analysts anticipate that Cardiff Oncology will post -0.99 EPS for the current year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.